{"title":"SGLT-2i与心血管结局:亚洲队列的荟萃分析","authors":"S. Ghosal, B. Sinha","doi":"10.15226/2374-6890/6/1/001123","DOIUrl":null,"url":null,"abstract":"Sir, Recent diabetes guidelines have upgraded the position of sodium glucose cotransporter 2 inhibitors (SGLT-2i) based on the publication of cardiovascular outcomes trials (CVOT). However, divergent signals have emerged from the 3 CVOTs. It is speculated that these differences were due to differing patient population and cardiovascular (CV) risk status, suggesting that the benefits of SGLT-2i were driven primarily by their effect on the pump (hospitalization for heart failure (hHF) and CV death) and not on the pipe (myocardial infarction, stroke & peripheral arterial disease). [1]","PeriodicalId":73731,"journal":{"name":"Journal of endocrinology and diabetes","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"SGLT-2i and Cardiovascular Outcomes: A Meta-Analysis of The Asian Cohort\",\"authors\":\"S. Ghosal, B. Sinha\",\"doi\":\"10.15226/2374-6890/6/1/001123\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sir, Recent diabetes guidelines have upgraded the position of sodium glucose cotransporter 2 inhibitors (SGLT-2i) based on the publication of cardiovascular outcomes trials (CVOT). However, divergent signals have emerged from the 3 CVOTs. It is speculated that these differences were due to differing patient population and cardiovascular (CV) risk status, suggesting that the benefits of SGLT-2i were driven primarily by their effect on the pump (hospitalization for heart failure (hHF) and CV death) and not on the pipe (myocardial infarction, stroke & peripheral arterial disease). [1]\",\"PeriodicalId\":73731,\"journal\":{\"name\":\"Journal of endocrinology and diabetes\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of endocrinology and diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15226/2374-6890/6/1/001123\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of endocrinology and diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15226/2374-6890/6/1/001123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
SGLT-2i and Cardiovascular Outcomes: A Meta-Analysis of The Asian Cohort
Sir, Recent diabetes guidelines have upgraded the position of sodium glucose cotransporter 2 inhibitors (SGLT-2i) based on the publication of cardiovascular outcomes trials (CVOT). However, divergent signals have emerged from the 3 CVOTs. It is speculated that these differences were due to differing patient population and cardiovascular (CV) risk status, suggesting that the benefits of SGLT-2i were driven primarily by their effect on the pump (hospitalization for heart failure (hHF) and CV death) and not on the pipe (myocardial infarction, stroke & peripheral arterial disease). [1]
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
